IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
IOVANCE BIOTHERAPEUTICS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from the issuance of common stock, net → financing reconciliation: $148,081,000.00Proceeds from the issuance of common stock under employee stock purchase plan → financing reconciliation: $861,000.00Proceeds from the issuance of common stock upon exercise of options → financing reconciliation: $26,000.00financing reconciliation → Net cash from financing activities: $143,623,000.00financing reconciliation → Tax payments related to shares withheld for vested restricted stock units: $5,345,000.00Maturities of investments → investing reconciliation: $135,000,000.00investing reconciliation → Purchase of investments: $185,607,000.00investing reconciliation → Purchase of property and equipment: $12,049,000.00Net cash used in operating activities → operating reconciliation: $132,915,000.00Stock-based compensation expense → operating reconciliation: $23,002,000.00Amortization of intangible assets → operating reconciliation: $11,432,000.00Depreciation and amortization of property and equipment → operating reconciliation: $6,607,000.00Prepaid expenses, other assets and long-term assets → operating reconciliation: $4,444,000.00Accounts payable → operating reconciliation: $4,070,000.00Excess and obsolescence reserve → operating reconciliation: $2,808,000.00Amortization of right of use asset → operating reconciliation: $2,778,000.00Loss on asset disposals → operating reconciliation: $670,000.00Unrealized foreign exchange loss (gain) → operating reconciliation: $437,000.00operating reconciliation → Net Loss: $126,360,000.00operating reconciliation → Accrued expenses and other liabilities: $29,653,000.00operating reconciliation → Trade accounts receivable: $19,671,000.00operating reconciliation → Inventory: $5,108,000.00operating reconciliation → Operating lease liabilities: $2,800,000.00operating reconciliation → Accretion of discounts and premiums on investments: $2,533,000.00operating reconciliation → Deferred tax benefit: $2,038,000.00operating reconciliation → Gain on loan forgiveness: $1,000,000.00Net cash used in investing activities → investing reconciliation: $62,656,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $169,058,000.00Net cash from financing activities → Cash sources and uses: $143,623,000.00Cash sources and uses → Exchange-rate effect: $337,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $116,773,000.00Cash sources and uses → Net cash used in investing activities: $62,656,000.00Cash sources and uses → Net cash used in operating activities: $132,915,000.00Depreciation and amortization of property and equipment: $6,607,000.00Depreciation & amortization+$6.61 MExcess and obsolescence reserve: $2,808,000.00Inventory write-downs+$2.81 MDeferred tax benefit: -$2,038,000.00Deferred income taxes−$2.04 MUnrealized foreign exchange loss (gain): $437,000.00FX transaction gain & loss+$437.00 KAmortization of intangible assets: $11,432,000.00Intangible amortization+$11.43 MLoss on asset disposals: $670,000.00Asset disposal gain & loss+$670.00 KGain on loan forgiveness: -$1,000,000.00Debt extinguishment gain & loss−$1.00 MAccretion of discounts and premiums on investments: -$2,533,000.00Investment discount & premium−$2.53 MOperating lease liabilities: -$2,800,000.00Operating lease liabilities−$2.80 MPrepaid expenses, other assets and long-term assets: $4,444,000.00Prepaid & other assets+$4.44 MNet Loss: -$126,360,000.00Net Loss−$126.36 MTrade accounts receivable: -$19,671,000.00Accounts receivable−$19.67 MInventory: -$5,108,000.00Inventories−$5.11 MAccounts payable: $4,070,000.00Accounts payable+$4.07 MAccrued expenses and other liabilities: -$29,653,000.00Accrued liabilities−$29.65 MStock-based compensation expense: $23,002,000.00Stock-based compensation+$23.00 MAmortization of right of use asset: $2,778,000.00Operating lease amortization+$2.78 MNet cash used in operating activities: -$132,915,000.00. Cash required to fund net payments.Operating cash−$132.92 Moperating reconciliation: $189,163,000.00Tax payments related to shares withheld for vested restricted stock units: -$5,345,000.00Stock-award tax withholding−$5.35 MProceeds from the issuance of common stock under employee stock purchase plan: $861,000.00Employee stock purchase proceeds+$861.00 KProceeds from the issuance of common stock upon exercise of options: $26,000.00Stock option exercises+$26.00 KProceeds from the issuance of common stock, net: $148,081,000.00Common stock issued+$148.08 MNet cash from financing activities: $143,623,000.00Financing cash+$143.62 Mfinancing reconciliation: $148,968,000.00Maturities of investments: $135,000,000.00AFS securities proceeds+$135.00 MPurchase of investments: -$185,607,000.00AFS securities purchases−$185.61 MPurchase of property and equipment: -$12,049,000.00PP&E purchases−$12.05 MNet cash used in investing activities: -$62,656,000.00. Cash required to fund net payments.Investing cash−$62.66 Minvesting reconciliation: $197,656,000.00Cash sources and uses: $312,681,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $169,058,000.00Beginning cash$169.06 MEnding cash: Cash, cash equivalents, and restricted cash: $116,773,000.00Ending cash$116.77 MExchange-rate effect: -$337,000.00FX effect−$337.00 KCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$126.36M − net operating adjustments $6.56M = operating cash −$132.92MFree cash flow−$144.96 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$52.29 MEnding cash − beginning cash
Chart details

IOVANCE BIOTHERAPEUTICS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
169,058,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 132,915,000 US dollars. Net cash used.
Net Loss
negative 126,360,000 US dollars
Depreciation and amortization of property and equipment
6,607,000 US dollars
Excess and obsolescence reserve
2,808,000 US dollars
Deferred tax benefit
negative 2,038,000 US dollars
Unrealized foreign exchange loss (gain)
437,000 US dollars
Amortization of intangible assets
11,432,000 US dollars
Loss on asset disposals
670,000 US dollars
Gain on loan forgiveness
negative 1,000,000 US dollars
Accretion of discounts and premiums on investments
negative 2,533,000 US dollars
Operating lease liabilities
negative 2,800,000 US dollars
Prepaid expenses, other assets and long-term assets
4,444,000 US dollars
Trade accounts receivable
negative 19,671,000 US dollars
Inventory
negative 5,108,000 US dollars
Accounts payable
4,070,000 US dollars
Accrued expenses and other liabilities
negative 29,653,000 US dollars
Stock-based compensation expense
23,002,000 US dollars
Amortization of right of use asset
2,778,000 US dollars
Investing activities
negative 62,656,000 US dollars. Net cash used.
Maturities of investments
135,000,000 US dollars
Purchase of investments
negative 185,607,000 US dollars
Purchase of property and equipment
negative 12,049,000 US dollars
Financing activities
143,623,000 US dollars. Net cash provided.
Tax payments related to shares withheld for vested restricted stock units
negative 5,345,000 US dollars
Proceeds from the issuance of common stock under employee stock purchase plan
861,000 US dollars
Proceeds from the issuance of common stock upon exercise of options
26,000 US dollars
Proceeds from the issuance of common stock, net
148,081,000 US dollars
Operating adjustment reconciliation
189,163,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
148,968,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
197,656,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 337,000 US dollars
Ending cash on Jun 30, 2026
116,773,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
312,681,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 52,285,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 132,915,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
12,049,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 144,964,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$126.36M − net operating adjustments $6.56M = operating cash −$132.92M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 132,915,000 US dollars minus 12,049,000 US dollars equals negative 144,964,000 US dollars.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!